Efficacy and Safety of Biologic Therapies in Severe Asthma: A Comparative Analysis of Treatment Outcomes in Pediatric and Adult Populations
DOI:
https://doi.org/10.70749/ijbr.v3i3.868Keywords:
Severe Asthma, Biologic Therapy, Asthma Exacerbations, FEVAbstract
Background: Severe asthma remains a major challenge, particularly for patients unresponsive to standard inhaled corticosteroids and long-acting bronchodilators. Biologic therapies targeting inflammatory pathways, such as IL-5, IL-4, and IgE, have shown promise in improving treatment outcomes. However, differences in response between pediatric and adult patients require further investigation. Objective: This meta-analysis evaluates the efficacy and safety of biologic therapies in pediatric and adult patients with severe asthma, comparing outcomes such as asthma exacerbations and lung function improvement (FEV₁). Methods: A systematic search across PubMed, Embase, Cochrane Library, and Web of Science identified randomized controlled trials (RCTs), cohort studies, and observational studies assessing biologic therapies in severe asthma. Statistical analyses, including pooled effect sizes and heterogeneity assessments, were performed using Review Manager (RevMan) and Stata software. Results: The meta-analysis included 10 studies with 12,932 patients (9,527 adults; 3,405 pediatric). Biologic therapies significantly reduced asthma exacerbations in both groups, though adults showed a stronger response (OR: 0.60 – 0.68, p<0.05) compared to pediatric patients (OR: 0.75 – 0.78, p<0.05). FEV₁ improvements were notable in pediatric patients (mean increase: 150 mL, p<0.05). Safety profiles were comparable between both groups, with no significant increase in severe adverse events. Conclusion: Biologic therapies effectively reduce exacerbation rates and improve FEV₁ in both pediatric and adult patients with severe asthma. However, treatment response appears stronger in adults, potentially due to differences in immune system maturity and medication adherence. Further research is needed to assess long-term efficacy and safety, particularly in pediatric populations.
Downloads
References
Busse, W. W., Maspero, J. F., Rabe, K. F., Papi, A., Wenzel, S. E., Ford, L. B., Pavord, I. D., Zhang, B., Staudinger, H., Pirozzi, G., Amin, N., Akinlade, B., Eckert, L., Chao, J., Graham, N. M. H., & Teper, A. (2018). Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Advances in Therapy, 35(5), 737–748. https://doi.org/10.1007/s12325-018-0702-4
Jackson, D. J., Wechsler, M. E., Jackson, D. J., Bernstein, D., Korn, S., Pfeffer, P. E., Chen, R., Saito, J., Gustavo, Dymek, L., Jacques, L., Bird, N., Stein Schalkwijk, Smith, D., Howarth, P., & Pavord, I. D. (2024). Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2406673
Fitzpatrick, A. M. (2016). Severe Asthma in Children: Lessons Learned and Future Directions. The Journal of Allergy and Clinical Immunology: In Practice, 4(1), 11–19. https://doi.org/10.1016/j.jaip.2015.10.008
Larenas-Linnemann, D., Rhee, C. K., Altraja, A., Busby, J., Tran, T. N., Wang, E., Popov, T. A., Mitchell, P. D., Pfeffer, P. E., Pleasants, R. A., Katial, R., Koh, M. S., Bourdin, A., Schleich, F., Máspero, J., Hew, M., Peters, M. J., Jackson, D. J., Christoff, G. C., . . . Price, D. B. (2025). International Severe Asthma Registry (ISAR): 2017-2024 status and progress update. Tuberculosis & Respiratory Diseases. https://doi.org/10.4046/trd.2024.0198
Kavanagh, J. E., Hearn, A. P., & Jackson, D. J. (2021). A pragmatic guide to choosing biologic therapies in severe asthma. Breathe, 17(4), 210144. https://doi.org/10.1183/20734735.0144-2021
Menzella, F., Ballarin, A., Sartor, M., Floriani, A. F., Corsi, L., Dartora, C., Tonin, S., & Romagnoli, M. (2022). Comparison between clinical trials and real-world evidence studies on biologics for severe asthma. Journal of International Medical Research, 50(11). https://doi.org/10.1177/03000605221133689
Fitzpatrick, A. M. (2016). Severe asthma in children: lessons learned and future directions. The Journal of Allergy and Clinical Immunology in Practice, 4(1), 11–19. https://doi.org/10.1016/j.jaip.2015.10.008
Larenas-Linnemann, D., Rhee, C. K., Altraja, A., Busby, J., Tran, T. N., Wang, E., Popov, T. A., Mitchell, P. D., Pfeffer, P. E., Pleasants, R. A., Katial, R., Koh, M. S., Bourdin, A., Schleich, F., Máspero, J., Hew, M., Peters, M. J., Jackson, D. J., Christoff, G. C., . . . Price, D. B. (2025). International Severe Asthma Registry (ISAR): 2017-2024 status and progress update. Tuberculosis & Respiratory Diseases. https://doi.org/10.4046/trd.2024.0198
Schepel, I. R., Banzon, T. M., & Phipatanakul, W. (2023). Future of biologics in pediatric asthma. Annals of Allergy Asthma & Immunology, 132(1), 13–20. https://doi.org/10.1016/j.anai.2023.08.597
Kavanagh, J. E., Hearn, A. P., & Jackson, D. J. (2021). A pragmatic guide to choosing biologic therapies in severe asthma. Breathe, 17(4), 210144. https://doi.org/10.1183/20734735.0144-2021
Hansen, S., Søndergaard, M. B., Von Bülow, A., Bjerrum, A., Schmid, J., Rasmussen, L. M., Johnsen, C. R., Ingebrigtsen, T., Håkansson, K. E. J., Johansson, S. L., Bisgaard, M., Assing, K. D., Hilberg, O., Ulrik, C., & Porsbjerg, C. (2023). Clinical response and remission in patients with severe asthma treated with biologic therapies. CHEST Journal, 165(2), 253–266. https://doi.org/10.1016/j.chest.2023.10.046
Perikleous, E. P., Steiropoulos, P., Nena, E., & Paraskakis, E. (2022). Biologic therapies in pediatric asthma. Journal of Personalized Medicine, 12(6), 999. https://doi.org/10.3390/jpm12060999
Nieto, A., El-Sayed, Z. A., Gómez, R. M., Hossny, E., Jiu-Yao, W., Kalayci, Ö., Morais-Almeida, M., Phipatanakul, W., Pitrez, P. M., Beltrán, C. F. P., Xepapadaki, P., & Papadopoulos, N. G. (2023). Unanswered questions on the use of biologics in pediatric asthma. World Allergy Organization Journal, 16(11), 100837. https://doi.org/10.1016/j.waojou.2023.100837
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
